Eikon Therapeutics reports Q4/FY2025 net loss $79.7M/$333.6M; IPO raised $381M

Eikon Therapeutics, Inc.

Net loss attributable to common stockholders was $79.7M in Q4 2025 and $333.6M for full year 2025.
Cash, cash equivalents and marketable securities $336M as of Dec 31, 2025; added $381.2M from IPO in Feb 2026.
Completed enrollment of TeLuRide-005 Phase 2 trial of EIK1001 in first-line stage 4 NSCLC; data expected 2H 2026.
R&D expenses $65.2M in Q4 2025 (+21% YoY); $250.3M for FY2025 (+22% YoY).
Elected David W. Meline (former CFO of Moderna, Amgen, 3M) as independent director in December 2025.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Eikon Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2025 results: net income Net loss attributable to common stockholders was $79.7 million for the fourth quarter of 2025.

Period: fourth quarter and full year ended December 31, 2025
Net income: Net loss attributable to common stockholders was $79.7 million for the fourth quarter of 2025
Result: reported results

Exact text from the filing

On March 30, 2026, Eikon Therapeutics, Inc. issued a press release announcing clinical and corporate updates and its financial results for the three months and full year ended December 31, 2025

View on SEC.gov

Browse all earnings releases →

Eikon Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-130449

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.